Current Issue

Older patients have increased hypoglycemia risk soon after beta-blocker initiation

Hypoglycemia risk nearly doubled in the immediate period after initiation of beta-blockers compared with long-standing use, and the risk was higher in patients who were also taking insulin, a Canadian study of older patients with type 2 diabetes found.

Switching to tirzepatide improves outcomes vs. escalating dulaglutide in type 2 diabetes

An industry-funded randomized trial found that switching to tirzepatide after inadequate response to dulaglutide led to significant additional reductions in HbA1c levels and weight at 40 weeks compared with increasing the dulaglutide dose.

Gastric bypass increased diabetes remission versus sleeve gastrectomy, small trial finds

At five years after gastric bypass, half of patients with type 2 diabetes and obesity had an HbA1c level less than 6%, compared to 20% of those randomized to sleeve gastrectomy, according to a secondary analysis of a Norwegian trial.

MKSAP quiz: Treatment of hypoglycemia

This month's quiz asks readers to evaluate a 70-year-old man with type 2 diabetes who develops sweating, tremors, and anxiety while visiting his hospitalized wife.

Spotlight on initiation of SGLT-2 inhibitors

One study found that initiation of a sodium-glucose cotransporter-2 (SGLT-2) inhibitor was associated with risk of infection of the genital tract but not the urinary tract compared to a glucagon-like peptide-1 receptor agonist, while another study indicated that a decline in estimated glomerular filtration rate without a drop in urine albumin-to-creatinine ratio could be a worrisome signal.

ED visits for semaglutide adverse events rare, study suggests

The majority of ED visits related to taking semaglutide were attributed to gastrointestinal complications and hypoglycemia.

In adults with HF with preserved ejection fraction and obesity, tirzepatide reduced a composite of CV death or worsening HF at 2 y

A manufacturer trial added to the evidence that incretin-based therapies improve cardiovascular (CV) outcomes in patients with obesity and heart failure (HF) with preserved ejection fraction, regardless of the presence of diabetes, an ACP Journal Club commentary said.

Warning on Dexcom CGM manufacturing

The FDA sent a warning letter about methods used in the manufacture, packing, storage, or installation of the G6 and G7 continuous glucose monitors (CGMs).